A study in patients with metastatic pancreatic ductal adenocarcinoma, where abraxane and gemcitabine chemotherapy will be administered either on the same day, or abraxane will be administered 24 hours before gemcitabine.
- Registry ID
- EUCTR2013-001868-40
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start date
- 2013-11-05
- Completion date
- 2017-03-27
- Last update
- 2026-08-16
Conditions
- metastatic pancreatic adenocarcinoma
Summary
The primary objective of the trial is to investigate the outcome of sequential administration of ABX combined with GEM (ABX/GEM) in patients with metastatic PDAC in terms of progression-free survival.
Locations
View on source registry